Cargando…
Immune checkpoint inhibitors in resectable gastroesophageal cancers - a review
Gastroesophageal cancers (GEC) have a poor survival rate of 20–30% at 5 years, often due to delayed presentations. Neoadjuvant chemoradiotherapy (CRT) followed by surgery or peri-operative chemotherapy and surgery are widely used as the standard of care for patients with resectable GEC. Immune check...
Autores principales: | Mukherjee, Sarbajit, Parmar, Kanak, Smyth, Elizabeth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9720835/ https://www.ncbi.nlm.nih.gov/pubmed/36479471 http://dx.doi.org/10.1177/17588359221139625 |
Ejemplares similares
-
Anti PD-1/Anti PDL-1 Inhibitors in Advanced Gastroesophageal Cancers: A Systematic Review and Meta-Analysis of Phase 2/3 Randomized Controlled Trials
por: Parmar, Kanak, et al.
Publicado: (2022) -
Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers
por: Sundar, Raghav, et al.
Publicado: (2020) -
Role of Checkpoint Inhibitors in the Management of Gastroesophageal Cancers
por: Karim, Frederic, et al.
Publicado: (2023) -
Pharmacogenomics based precision medicine in gastroesophageal cancers: way to move forward?
por: Shah, Shrunjal, et al.
Publicado: (2020) -
Immunotherapy for Gastroesophageal Cancer
por: Goode, Emily F., et al.
Publicado: (2016)